The ABIO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABIO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ABIO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ABIO Detailed Price Forecast - CNN Money||View ABIO Detailed Summary - Google Finance|
|View ABIO Detailed Summary - Yahoo! Finance||View ABIO Stock Research & Analysis - Zacks.com|
|View ABIO Trends & Analysis - Trade-Ideas||View ABIO Major Holders - Barrons|
|View ABIO Call Transcripts - NASDAQ||View ABIO Breaking News & Analysis - Seeking Alpha|
|View ABIO Annual Report - CompanySpotlight.com||View ABIO OTC Short Report - OTCShortReport.com|
|View ABIO Fundamentals - TradeKing||View ABIO SEC Filings - Bar Chart|
|View Historical Prices for ABIO - The WSJ||View Performance/Total Return for ABIO - Morningstar|
|View the Analyst Estimates for ABIO - MarketWatch||View the Earnings History for ABIO - CNBC|
|View the ABIO Earnings - StockMarketWatch||View ABIO Buy or Sell Recommendations - MacroAxis|
|View the ABIO Bullish Patterns - American Bulls||View ABIO Short Pain Metrics - ShortPainBot.com|
|View ABIO Stock Mentions - StockTwits||View ABIO Stock Mentions - PennyStockTweets|
|View ABIO Stock Mentions - Twitter||View ABIO Investment Forum News - Investor Hub|
|View ABIO Stock Mentions - Yahoo! Message Board||View ABIO Stock Mentions - Seeking Alpha|
|View Insider Transactions for ABIO - SECform4.com||View Insider Transactions for ABIO - Insider Cow|
|View ABIO Major Holdings Summary - CNBC||View Insider Disclosure for ABIO - OTC Markets|
|View Insider Transactions for ABIO - Yahoo! Finance||View Institutional Holdings for ABIO - NASDAQ|
|View ABIO Stock Insight & Charts - FinViz.com||View ABIO Investment Charts - StockCharts.com|
|View ABIO Stock Overview & Charts - BarChart||View ABIO User Generated Charts - Trading View|
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced it recently filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering Gencaro’s (bucindolol hydrochloride) potential treatment effect in preventing atrial fibrillation (AF) in patients with heart failure (HF). The patent application is based on recent novel findings from the GENETIC-AF Phase 2B study of Gencaro, described in “GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population,” published in JACC: Heart Failure, a journal of the American College of Cardiology.
ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update
Posted on Wednesday May 08, 2019
WESTMINSTER, Colo., May 08, 2019 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.
GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure
Posted on Wednesday May 01, 2019
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper “GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population” was published in JACC: Heart Failure, a journal of the American College of Cardiology. The lead author on the paper is Jonathan P. Piccini, MD, MHS, FACC, Director, Duke Center for Atrial Fibrillation, Duke University Medical Center and Duke Clinical Research Institute and the senior author is Stuart J. Connolly, MD, Professor Emeritus, Division of Cardiology at McMaster University in Hamilton, Ontario.
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the initial members of the Steering Committee for PRECISION-AF, the Company’s planned Phase 3 trial evaluating Gencaro™ (bucindolol hydrochloride) as potentially the first genetically-targeted treatment for atrial fibrillation. The Steering Committee is comprised of experts in the field of cardiology and electrophysiology, particularly in clinical development. The Company anticipates additional cardiology thought leaders joining the Steering Committee.